Vol. 8, Issue 1, Part A (2026)

The introduction of biosimilars has transformed the treatment options for chronic diseases, including cancer, autoimmune disorders, and various conditions that necessitate biologic therapies. As healthcare systems around the globe work towards providing affordable treatments, the role of biosimilars in clinical practice is increasingly significant. Biosimilars are closely comparable to reference products, featuring slight variations in non-active components, while exhibiting no clinically relevant differences regarding safety, purity, and effectiveness. This review seeks to offer a thorough examination of biosimilars in contemporary medicine, emphasizing their development, regulatory guidelines, clinical effectiveness, and safety assessments. By exploring the existing situation of biosimilar approvals, their influence on healthcare systems, and the obstacles that hinder their acceptance. Our findings indicate that biosimilars can enhance access to essential therapies, lower healthcare expenses, and better patient outcomes. Nevertheless, challenges related to interchangeability, naming practices, and the education of healthcare providers and patients deserve attention. This review concludes that biosimilars are an essential element of modern medicine, presenting a hopeful remedy to the rising costs of biologic therapies, and highlights the necessity for ongoing research, education, and policy advocacy to fully capitalize on their advantages.